NASDAQ$XERS
Xeris Biopharma Holdings Inc · Q2 2023 earnings
Q2 2023 earnings · · Investor relations
Briefing
Achieved record revenue with a 14% increase from prior quarter and a 50% increase from same period prior year.
Xeris Biopharma reported record revenue of $38.0 million for Q2 2023, a 50% increase compared to the same period last year. The company is tightening its full-year 2023 guidance, expecting total net revenue between $145M and $165M and anticipates reaching cash flow breakeven by the end of 2023.
- Record revenue achieved due to strong demand for all three products and partnership contributions.
- Gvoke prescriptions topped 51,000, growing 50% compared to the same period in 2022.
- Keveyis revenue increased 10% compared to the same period in 2022.
- Recorlev revenue increased by $6.2 million compared to the second quarter of 2022, its first full quarter since launch.
Headline financials
Revenue & EPS history
Xeris Biopharma · Revenue · Quarterly
$36.9M
Revenue by segment
Xeris Biopharma · $36.9M total across 3 segments · Q2 2023
- Gvoke$15.6M+36.2%42.4%
- Keveyis$14.1M+10.0%38.2%
- Recorlev$7.17M+639.6%19.4%
Forward guidance
Xeris Biopharma is tightening its full-year 2023 financial guidance.
Tailwinds
- Total net revenue expected to be between $145 million and $165 million.
- Cash utilization projected to be between $57 million and $67 million.
- Year-end cash balance anticipated to be between $55 million and $65 million.
- Company expects to reach cash flow breakeven point in the fourth quarter.
- Company aims to continue being a self-sustaining enterprise.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 20 quarterly earnings reports · overlaid with Q2 2023
-0.8%
Avg return
Earnings day
+2.1%
Avg return
5 days after
+4.5%
Avg return
30 days after
40%
12 / 30 earnings
Positive
+33.5%
Q1 2020
Best reaction
-21.8%
Q3 2025
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q1 2026 | +4.1% | -1.9% | -3.1% | |
| Q4 2025 | -2.0% | -5.1% | -1.3% | |
| Q3 2025 | -21.8% | -24.6% | -34.0% | |
| Q1 2025 | +15.2% | +9.4% | +2.2% | |
| Q4 2024 | +9.5% | +16.4% | +17.0% | |
| Q3 2024 | -2.4% | -6.2% | +9.2% | |
| Q2 2024 | +8.9% | +19.2% | +17.8% | |
| Q1 2024 | -4.9% | +2.7% | +25.9% | |
| Q4 2023 | -20.8% | -26.9% | -33.8% | |
| Q3 2023 | -14.9% | -21.2% | +2.5% | |
| Q2 2023 | -5.6% | -8.4% | -14.1% | |
| Q1 2023 | +22.1% | +20.8% | +22.9% | |
| Q4 2022 | -18.3% | -20.9% | +23.5% | |
| Q3 2022 | +0.0% | -5.3% | -3.3% | |
| Q2 2022 | +7.1% | +11.2% | +7.1% | |
| Q1 2022 | -15.1% | +23.5% | +5.6% | |
| Q4 2021 | +9.3% | +8.1% | -4.5% | |
| Q3 2021 | +6.1% | +26.5% | +13.3% | |
| Q2 2021 | -18.9% | -18.9% | -4.6% | |
| Q1 2021 | +3.3% | +7.8% | +18.6% | |
| Q4 2020 | -8.1% | +1.9% | -9.7% | |
| Q3 2020 | -0.9% | -3.1% | -26.1% | |
| Q2 2020 | -1.8% | +25.1% | +43.6% | |
| Q1 2020 | +33.5% | +62.8% | +100.0% | |
| Q4 2019 | -10.9% | -21.9% | -2.5% | |
| Q3 2019 | -10.1% | -8.2% | -1.9% | |
| Q2 2019 | -1.4% | +5.9% | +5.9% | |
| Q1 2019 | +13.3% | +13.3% | -22.8% | |
| Q4 2018 | -5.8% | -10.4% | -6.2% | |
| Q3 2018 | +5.8% | -9.3% | -13.0% | |
| Q2 2017 | — | — | — | |
| Q1 2017 | — | — | — | |
| Q4 2017 | — | — | — | |
| Q3 2017 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro